SCHEMBL4354202

SCHEMBL4354202

O=C1N=C(N2CCN(c3ccccc3F)CC2)SC1=CC(Cl)=Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 4/20 0.53
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
HCRTR1 O43613 1/20 0.53
DCTPP1 Q9H773 1/20 0.46
GRIN1 Q05586 3/20 0.45
GRIN2B Q13224 3/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
SENP1 Q9P0U3 1/20 0.43
HTT P42858 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364702 0.84 MAPT (0.58) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4359669 0.83 MAPT (0.76) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4362316 0.80 MAPT (0.73) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4353893 0.79 MAPT (0.51) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4350031 0.75 MAPT (0.69) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4350035 0.75 MAPT (0.69) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4352779 0.74 MAPT (0.56) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4352782 0.74 MAPT (0.56) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4352217 0.73 ALDH1A1 (0.71) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4352214 0.73 ALDH1A1 (0.71) MAPTNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885NPC1 326/4885RAB9A 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.